Last reviewed · How we verify

EffCaMgCit — Competitive Intelligence Brief

EffCaMgCit (EffCaMgCit) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineral supplement / Nutritional formulation. Area: Bone Health / Metabolic Health.

phase 3 Mineral supplement / Nutritional formulation Bone Health / Metabolic Health Small molecule Live · refreshed every 30 min

Target snapshot

EffCaMgCit (EffCaMgCit) — University of Texas Southwestern Medical Center. EffCaMgCit is a combination supplement that provides bioavailable forms of calcium, magnesium, and citrate to support mineral homeostasis and bone health.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EffCaMgCit TARGET EffCaMgCit University of Texas Southwestern Medical Center phase 3 Mineral supplement / Nutritional formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineral supplement / Nutritional formulation class)

  1. University of Texas Southwestern Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EffCaMgCit — Competitive Intelligence Brief. https://druglandscape.com/ci/effcamgcit. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: